Status:

TERMINATED

A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

Lead Sponsor:

Eli Lilly and Company

Conditions:

Nakajo-Nishimura Syndrome

Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome

Eligibility:

All Genders

6+ years

Phase:

PHASE2

PHASE3

Brief Summary

The main purpose of this study is to evaluate the efficacy and safety of baricitinib in adult and pediatric Japanese participants with Nakajo-Nishimura Syndrome/chronic atypical neutrophilic dermatosi...

Eligibility Criteria

Inclusion

  • Have systemic signs and symptoms of inflammation as manifested NNS/CANDLE, SAVI, AGS
  • Have been diagnosed with genetic diagnosis
  • Men must agree to use a reliable method of birth control during the study
  • Women not of child-bearing potential or nonbreastfeeding
  • Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
  • NNS/CANDLE and SAVI patients who are ≥17.5 months of age
  • AGS patients who are ≥6 months of age
  • Are ≥ 5kg in body weight

Exclusion

  • Have received immunosuppressive biologic agent/monoclonal antibody/oral JAK inhibitor/OAT3 inhibitor and cannot discontinue prior to investigational product initiation. Note: A washout period is required to each drug.
  • Have diagnosis of current active tuberculosis (TB) or, latent TB who did not receive appropriate treatment.
  • Have had a serious infection within 12 weeks prior to screening.
  • Have a history of lymphoproliferative disease
  • Have any history of venous thromboembolic event (VTE) (deep vein thrombosis \[DVT\]/pulmonary embolism \[PE\]) prior to screening.
  • Have had any major surgery within 8 weeks prior to screening.
  • Have previously been enrolled in any other study investigating baricitinib.

Key Trial Info

Start Date :

October 27 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 28 2024

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT04517253

Start Date

October 27 2020

End Date

November 28 2024

Last Update

July 10 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Nara Medical University Hospital

Kashihara, Nara, Japan, 634-0813

2

Tokyo Medical And Dental University Medical Hospital

Bunkyō, Tokyo, Japan, 113-8519

3

National Center For Child Health And Development

Setagaya-ku, Tokyo, Japan, 157-8535

4

Hiroshima University Hospital

Hiroshima, Japan, 734-8551